Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.
Back to Lifestyle
Lifestyle
November 12, 2026 at 11:30 AM
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
STAT News
Excerpt from STAT News.